Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Blackheath’s arbitrage strategy fund in spectacular finish in November, up 28.74% YTD

Tuesday, December 11, 2012

From Komfie Manalo, Opalesque Asia:

November was a solid, if not spectacular month for Blackheath’s Volatility Arbitrage Strategy Fund after posting 28.74% gains 11 months into 2012 (+2.49% in November). The fund is managed by Blackheath Fund Management, a Canadian managed futures advisory firm.

In his monthly report to investors, Blackheath Portfolio Manager and Director Andrew Cumming said that if the fund put up this performance every month, they would be returning 30% ever year. The Volatility Arbitrage Strategy has an estimated $19m in assets as at end November, while Blackheath Fund Management’s total AuM was estimated at $53.7m.

"The prevailing theme this past month has been low implied volatility across all markets," he told investors. In addition, he added, "We are booking trades with core implied volatilities at or below any we have seen since the inception of this strategy. This is also reflected in the various volatility indices we track, all of which matched or exceeded 5-year lows at some point over this past month. Some of this low volatility is emblematic of complacency on the part of investors because of the perception that, with the continued quantitative easing and stimulus spending programs in place in many parts of the world, asset prices will not be allowed to significantly contract without spurring more support."

The fund’s exposure in U.S. long bond, crude oil and Canadi......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for